DEFA14A: Hologic to Go Private in $18B Blackstone, TPG Acquisition

Hologic, a women's health technology company, has agreed to be acquired by investment firms Blackstone and TPG for up to $79 per share, valuing the company at over $18 billion.

Summary

• Hologic, Inc. has agreed to be acquired by Blackstone and TPG.
• The transaction values Hologic at up to $79 per share, comprising $76 upfront cash and a Contingent Value Right (CVR) of up to $3 per share.
• The total enterprise value of the transaction is up to over $18 billion.
• The CVR payments, up to $1.50 each, are contingent on Breast Health revenue performance in fiscal years 2026 and 2027.
• The acquisition is expected to close in the first half of calendar year 2026, after which Hologic will become a private company.

Sentiment

Score: 9

Explanation: The filing announces a significant acquisition at a premium, framed as an 'excellent opportunity' with strong positive language regarding future growth, innovation, and benefits for all stakeholders, including employees and stockholders. The tone is overwhelmingly optimistic about the company's future under private ownership.

Positives

• Stockholders receive immediate and compelling value, with the transaction valuing Hologic at up to $79 per share.
• The acquisition by Blackstone and TPG is expected to strengthen Hologic's leadership in women's health and accelerate growth.
• Hologic anticipates being better positioned globally with fewer capital constraints and additional resources for investment in growth and innovation as a private company.
• The acquirers, Blackstone and TPG, have deep healthcare expertise and a commitment to long-term innovation, which is expected to enhance Hologic's ability to deliver critical medical technologies.
• For the vast majority of employees, the change is expected to be seamless, with day-to-day jobs remaining largely the same, and a long-term positive outlook.
• The transaction is expected to bolster product positions, accelerate the pipeline, broaden international reach, and strengthen capacity for strategic acquisitions.

Negatives

• Hologic will cease to be a publicly traded company upon closing, removing its stock from public exchanges.
• The CVR component of up to $3 per share is contingent on future Breast Health revenue performance in FY26 and FY27, meaning the full $79 per share is not guaranteed.
• The transaction is subject to various risks and uncertainties, including regulatory approvals and stockholder approval, which could delay or prevent its consummation.

Risks

• The timing, receipt, and terms of required governmental and regulatory approvals could delay or cause the parties to abandon the proposed transaction.
• The occurrence of any event, change, or other circumstances could give rise to the termination of the merger agreement.
• Hologic stockholders may not approve the proposed transaction.
• The parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• Disruption of management time from ongoing business operations due to the proposed transaction.
• Any announcements relating to the proposed transaction could have adverse effects on the market price of Hologic's common stock.
• Unexpected costs or expenses resulting from the proposed transaction.
• Litigation relating to the proposed transaction.
• The proposed transaction and its announcement could adversely affect Hologic's ability to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders, and other business relationships.
• Holders of the CVRs may receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.

Future Outlook

Hologic expects to achieve faster growth as a private company by bolstering product positions, accelerating its pipeline, broadening international reach, and strengthening its capacity for strategic acquisitions, supported by the resources and expertise of Blackstone and TPG.

Management Comments

• Blackstone and TPG are fully committed to supporting our Purpose, Passion and Promise.
• They believe we have built a remarkable company, and that our people and products play an indispensable role in advancing womens health.
• Their operating model is to work with management teams to improve results.

Industry Context

This acquisition reflects a broader trend of private equity firms, particularly those with deep sector expertise like Blackstone and TPG in healthcare, investing in established medical technology companies. Such transactions often aim to accelerate growth and innovation away from public market pressures, leveraging significant capital and operational expertise to enhance market leadership, expand product pipelines, and increase global reach in specialized sectors like women's health.

Stakeholder Impact

• Shareholders: Will receive immediate and compelling value of up to $79 per share, with the company transitioning to private ownership.
• Employees: Expected to experience a seamless change, with day-to-day jobs largely remaining the same, and a long-term positive outlook due to accelerated growth and resources.
• Customers and Patients: Expected to benefit from enhanced ability to deliver critical medical technologies, strengthened leadership in women's health, and accelerated innovation.
• Vendors and Partners: Face a risk that the transaction and its announcement could adversely affect relationships.

Next Steps

• Hologic will continue to run its business as usual, operating independently from Blackstone and TPG until the transaction closes.
• Hologic will file a Proxy Statement with the SEC, which stockholders are urged to read for important information regarding the proposed transaction.
• Stockholders will need to approve the proposed transaction.
• Blackstone and TPG will work with Hologic's management team to improve results post-acquisition.

Key Dates

Recommendation

The company is being acquired at a fixed price (plus a contingent component), which limits significant upside potential for current shareholders beyond the announced offer. Holding the stock allows shareholders to realize the acquisition value upon closing, while a 'buy' might be considered for arbitrage if the current market price is below the upfront cash component, assuming the deal closes as expected.

Keywords

Hologic, Blackstone, TPG, Acquisition, Merger, Private Equity, Women's Health, Medical Technology, CVR, Healthcare Investment